Pilot study of the optimum hematocrit for patients in the predialysis stage after renal transplantation

Transplantation Proceedings

Volumn 36, Issue 5, 2004, Pages 1293-1296

  Kawaguchi, T ^a   Moriyama, T ^b,c   Suzuki, K ^a   Hatori, M ^a   Tanaka, T ^a   Takahara, S ^b   Yamanaka, H ^a  

^a GUNMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Department of Medical Science II   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HEART FUNCTION; HEMATOCRIT; HEMOCONCENTRATION; HEMODIALYSIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MALE; PATIENT SELECTION; PILOT STUDY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT OUTCOME;

ANEMIA; CHILD; ECHOCARDIOGRAPHY; ERYTHROPOIETIN, RECOMBINANT; HEMATOCRIT; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PILOT PROJECTS; POSTOPERATIVE PERIOD; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 3142530382     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.04.089     Document Type: Article

References (11)

1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia in Chronic Kidney Disease, 2000. Am J Kidney Dis. 37:(Suppl 1):2001;S182
2. Hayashi T., Suzuki A., Shoji T., et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 35:2000;250
3. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Med Care. 30:1992;473
4. Fukuhara S., Bito S., Green J., et al. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol. 51:1998;1037
5. Fukuhara S., Ware J.E., Kosinski M., et al. Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol. 51:1998;1045
6. Portoles J., Torralbo A., Martin P., et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 29:1997;541
7. Fujisawa M., Ichikawa Y., Yoshiya K., et al. Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey. Urology. 56:2000;201
8. Silberberg J.S., Barre P.E., Prichard S.S., et al. Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int. 6:1989;286
9. McMahon L.P., Mason K., Skinner S.L., et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant. 15:2000;1425
10. Foley R.N., Parfrey P.S., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 58:2000;1325
11. Ponticelli C., Villa M. Role of anaemia in cardiovascular mortality and morbidity in transplant patients. Nephrol Dial Transplant. 17:(Suppl 1):2002;41